Elranatamab Efficacy in MagnetisMM-3 Compared with Real-World Control Arms in Triple-Class Refractory Multiple Myeloma - supplementary material

Supplementary Table 1. Most common physician’s choice treatment regimens observed in COTA and FH databases.Supplementary Table 2. Restricted mean survival time comparison of progression-free survival and overall survival between patients receiving elranatamab in the MagnetisMM-3Cohort A and physician’s choice in the COTA real-world external control arm.Supplemental Figure 1. Progression-free survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.Supplemental Figure 2. Overall survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.

补充表1. COTA与FH数据库中观测到的最常见医生选择治疗方案。补充表2. 针对MagnetisMM-3研究队列A中接受埃兰妥单抗（elranatamab）治疗的患者，与COTA真实世界外部对照臂中采用医生选择方案的患者，对比二者无进展生存期（Progression-Free Survival, PFS）与总生存期（Overall Survival, OS）的限制平均生存时间。补充图1. 经多重插补与逆概率治疗加权（Inverse Probability of Treatment Weighting, IPTW）处理后，MagnetisMM-3研究中接受埃兰妥单抗治疗的患者与FH数据库中真实世界医生选择方案治疗患者的无进展生存期差异。补充图2. 经多重插补与逆概率治疗加权处理后，MagnetisMM-3研究中接受埃兰妥单抗治疗的患者与FH数据库中真实世界医生选择方案治疗患者的总生存期差异。